The activity of the glycoprotein degrading lysosomal hydrolase, 4-L-aspartylglycosylamine amido hydrolase (AADGase, EC.3.5.1.26). was measured in plasma, buffy coat leukocytes, and separated lymphocytes (Ficoll separation) from 16 patients with aspartylglucosaminuria I A G U ), 29 obligate heterozygotes, and 30 control subjects. I n lymphocytes the A G U patients had unmeasurable or minimal AADGase activity with a mean of 3.9 U. The obligate heterozygotes showed AADGase activities ranging from 5 to 69 U with a mean of 34.1 U. Enzyme activities i n the control group ranged from 91 to 243 11 with a mean of 127.9 U, and were clearly separated from the talues of the heterozygotes.
I n leukocytes the AGU patients had unmeasurable enzyme activity and obligate heterozygotes had enzyme levels closely similar to those in the lymphocytes from the same individuals. The AADGase activity in the leukocytes of the control group displayed a n~uch wider rariatioii than i n :hc lymphccytes, raaging from 22 to 132 Li with a mean of 70.7 U. I n plasma the AGU patients had undetectable AADGase activity.
The mean enzyme letel of obligate heterozygotes was 72.2 U and that of control indibiduals 107.2 U, but the oterlap between the groups was extensive. The results indicate that homozygous deficiency of AADGase, i.e., aspartylglucosaminuria, can be reliably diagnosed using plasma, leukocytes, or separated lymphocytes. For carrier detection only separated lymphocytes allow a satisfactory differentiation between heterozygous and normal individuals.
A group of 31 siblings of verified A G U cases and 11 children o f identified carriers, whose spouses had normal AADGase activity, were investigated using the lymphocyte assay. The observed and expected frequencies (on the basis o f Mendelian probabilities) were closely similar, suggesting that the lymphocyte assay can be used reliably for carrier detection.
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Demonstration of AADGase deficiency in plasma or in white blood cells offers an alternatire method for the diagnosis of aspartylglucosaminuria. Large scale screening programs for AGU carrier detection with the lymphocyte enzyme assay are not considered practical and justified at present. Carrier screening among relatives of known A G U patients is, however, medically, econcmically, and psychologically advantageous, particularly since prenatal diagnosis and the possibility of pretentive abortion can be offered to carrier-carrier matings.
Deficiency of the lysosomal enryme, 4-L-aspartylglycosylamine amido hydrolase, causes a disturbance of glycoprotein catabolism and leads to a clinical disease, A G U . The clinical features of A G U include slowly progressive psychomotor retardation starting at the age of 2 6 years and resulting in severe mental retardation before puberty. This psychomotor impairment is associated with the appearance of typical coarse facial features and degenerative changes in connective tissue (3). The disease was first described in two mentally retarded siblings in England (10) . Subsequent patients have been found almost exclusively in Finland, where a total of 82 cases has been verified. Very recently, however, the first cases of A G U have been detected in the U S A (9) and in Norway (12) . T h e diagnosis of A G U has generally been based on the demonstration of increased urinary excretion of aspartylglycosylamine by chromatographic o r electrophoretic methods (17) . The same glycopeptide is the main storage material in brain and liver tissue, but small amounts of some higher glycoasparagines also accumulate ( 18) .
T h e enzyme deficier~cy has been demonstrated in plasma and seminal fluid (2 I), as well as in liver, brain, and spleen tissue (19) of A G U patients. The enzyme defect is also expressed in cultured fibroblasts. which offers the possibility of prenatal diagnosis (2).
Fibroblasts from parents of A G U patients have an intermediate activity of AADGase, which proves the autosomal recessive mode of inheritance of the disease and provides a basis for heterozygote detection (I).
In order t o avoid the practical difficulties associated with cell culture techniques, we have assessed the suitability of plasma, leukocytes. and lymphocytes for the enzymatic diagnosis and carrier detection of A G U . Earlier data had already suggested that A A D G a s e activity in the plasma of obligate heterorygotes was not different from control individuals (20) .
M A T E R I A L A N D M E T H O D S
The subjects studied consisted of 16 patients with clinically and biochemically verified A G U , 29 parents of patients (obligate heterozygotes), and 30 control individuals. At a later stage of the study. 31 healthy sihiings of A G U patients and i l offsprings o i identified carriers whose spouses had normal AADGase values were investigated with the lymphocytes assay.
P R E P A R A T I O N OF S A M P L t S
Peripheral venous blood (10 ml) was drawn into a heparinized syringe and used for the preparation of cell extracts. Leukocyterich plasma was separated from the erythrocytes by letting the syringe stand at room temperature for 60 min. Leukocytes and plasma were then separated by centrifugation at 1,500 rpni for 10 min. The cells were washed twice with phosphate-buffered saline before counting and sonication. Lymphocytes were separated from another 10-ml blood sample by centrifugation using the one-step Ficoll-Isopaque method described by Boyum ( 5 ) . T h e yield of -lo6 cells. For elimination of possible erythrocyte contamlnation both lymphocytes and leukocytes were treated with 0.83C' amrnonium chloride for 15 niin s t 37'.
Cell extracts were prepared by sonication after adding Triton X-100 to a final concentration of 0. I % t o the cell suspension. The sonicates were used for enLyme assays and protein determination (13) . For the plasma assays, aliquots of 200 were used.
E N L Y M E ASSAYS
AADGase assay was originally described by Makino and coworkers (14) . and a detailed account of our assay system has been reported ( I ) . The synthetic substrate (2-acetamido-N-(Laspart-4'-oyl)-2-deoxy-P-_plucopyranosqlamine) was kindly provided by Professor I . Yamashina (Kyoto University. Kyoto, Japan).
One unit of enryme activity is defined as I nmol 1%'-acetjlglucosamine libernted/min/g sonicate protein; in plasma 1 U activity is expressed per PI! plasma. h'-Acetyl-@-glucosaminidase was assayed in all samples 3s a cell viability control using the commerciall) available p-nitrophenll derivative as substrate (19) . I n most cases lymphocytes and leukocytes were separatcd and used for enzyme determinations immediatelj after the blood was drawn, otherwise the extracts were stored at 7 0 ' for 1 7 days without loss of activity. In a few cases, the blood sample was kept overnight at room temperature. Storage of blood for periods longer than 24 hr was shown t o decrease the enzyme activities.
R ES CJ L T S AADCinse A C T I V I T Y I N L Y M P H O C Y T E S
All the A G U patients studied had unmeasurable o r minimal AADGase activity in lymphocytes, with a mean of 3.9 U (Fig. I) . This represents 3 % of the mean activity in control samples. T h e highest activity of 16 U was found in a 22-)ear-old female patient.
Unfortunatel!, the leukocytes and plasma ol' this case were not available for study.
The parents of A G U patients (obligate heterozygotes) showed AADGase activities ranging from 5 to 69 U , with a nieun of 34.1 U . An exceptionally low value of 5 U was found in one mother.
T h e blood in this case was stored overnight before lymphocyte separation which possibly accounts !-r the low enzyme ~!c!ivit! AADCiase activities in the Iqmphocytes of the control group ranged from 91 to 243 U. with a mean ol' 127.9 U, and were clearly separated from the values of the heterozygotes.
AADCiasr A C T I V I T Y I N L E U K O C Y T E S
Ail four A G U patlents studied had unmeasurable AADCrase activity in leukocytes. Obligate heterorygotes had enzyme levels closely similar to those in the lymphocytes from the same individuals, ranging from I to 65 U with a mean of 38.8 U . However, the AADGase activity in the leukocytes of the control group displayed a much wider variation than that in the lymphocytes, ranging from 22 to 132 U with a mean of 70.7 U . As depicted in Figure 1 , there is considerable overlap between the leukocyte AADGase values of obligate heterozygotes and control individuals. T o conclude, the results indicate that hornorygous del'iciencq of A A D G i t x . i.r.. ;~sp:trtqIgIucosani~nuria, can be reliably diagnosed using plasma. leukocyte\, o r separated lymphocytes. However. fur carrier detection. only separated I!mphocqtes allon it satisfactory differentiation between hetero/)fotes ~t n d normal ~ndividuals.
A jeveral-fold increase in the ~~ctivitq of this enryme \$as earller found in liver and brain tissue of A<iU patients (19) . In the present stud) a slight11 elevated le\,el of '2'-acetyl-fl-glucosaminidase was demonstrated in both 1eukoc)tes and I>mphocytes, with a mean * S D of 18.0 * 5.3 and 20.3 i 14.6 nriiol/rnin/nip protein.
respectively. T h e corresponding values In the control group n e r e 9. O n the basis of the data presented above, AADGase assa! using lymphocyte extracts was considered to fulfill the criteria of a reliable heterorygote test. The assessment of the genotype was based on the distribution of values in obligate heteroqgotes: any individual with AADGase activity 3 S D o r more above the mean of obligate heterorygotes ( > 8 7 . 2 U ) was designated normal. The probability of a false negative carrier assessment with this criterion is 0.1% o r less. Individuals with enzyme activitk between 1.5 S D and 3 S D above the mean of obligate hetero/ygotes (from 60.7 to 87.2 U ) were called "inconclusive." In these cases the probability of a false negative carrier assessment is between 7.9% and 0.1 '8 and restudy using a neu Iymphocqte sample o r CLIItured skin fihroblasts is required. ADDGase activ~tq less than 1.5 S D above the mean of obllgate heterorygotes ( <60.7 U ) was considered t o Indicate a carrier genotqpe. Using this value as the cutoff point, the risk of a normal indiv~dual b c~n g labeled a heterozqgote M;IS calculated to be 2.5'; or l e s~, based on the distribut~on of value\ In the control group. A simrlar c;irrier assessment s!stern has been used by Kaback and coworkers in heterorqgotc screening projects for Tay-Suchs gene ( I I ) .
A group of 3 1 siblings of verified A G U cases and I I children ol' identified carriers hose spouses had normal AADCiase activity were investigated using the Iqniphocyte enlqme assa). The o hserved number and frequencb of heterorygotes was compared with those expected on the basis of Mendelian probabilities. The re\ults are given in Table I . The expected and observed frequencie\ of A G U carriers are closely similar, suggesting that the lymphocqte assay can be used reliably for carrier detection.
Two cases out of a total of 42 fell within the "~nconclusive" range 01' AADGase activit). as shonn in Figure 2 . O n e daughter of an identified carrier had AADGase activ~t! of 71 U in the first assaq, but in a later repeat stud! the activit! was 123 U , indicating a norrn:rl AADGase genotype. T h e other "inconclusive" case Mas a female sibling of an A G U patient having AADGase activit) of 76 U . It has not yet been possible to perform a repeat test, but she is verq likel! a carrier because her daughter was shown t o have Iymphockte AADGase activit! of 40 U and her husband, normal activtt! of I03 U .
The demonstration of AADGase defic~cncy in plasma o r in white cells h a a number of practical iniplications. It offers an alternative method for the diagnosis of aspart! lglucosaminur~a. As mentioned earlier. this has so far been hased on the demonstration of increased amounts 01' aspartqlglucosqlam~ne ( A A D G ) in the urine. Screening tests for this purpose have been developed ( 8 ) . Even though incrnsed A A D G excretion has not heen encountered under other conditions. demonstration of the enrqrne defect is a more basic k a t u r e of the disease and thus prekrahle for diagno'itic purpo\es. Furthermore, it is not known whether A A D G excretion is elev:~ted alreadq during the "s~lent" period between birth and appearance of the first s y n s of the d~sease. The age of onset of clinical manifestations is known to be variable. ranging froni some months t o 6 years (3). O u r results demonstrate that A G U patients have undetectable o r minimal enzyme activity both in plasma. buff) coat leukocytes. and separated lymphocytes. There was. however, some overlap between iymphocyte i\i\liGabe aciivit! of 4C;U hornoz)gote\ and heterozy:otes. It is therefore advisable t o aasaq for A A D G a s i both in plasma and in l!mphoc!trs in the case of an asymptomatic newborn o r infant suspected of being affected by A G U .
A nractical and reliable carrier test of ACiU is needed. at least in ~inla'nd. where the disease is the most common known metabolic disorder leading to severe psychomotor retardation. The urinary excretron of AADCi in obligate heterozqgotes is not different from normal individuals ( 3 ) and thus the only possibilit! to show heterorygosity is the demonstration of intermediate levels of enzyme activity. The accuracy of our lynlphocyte assay in A G U carrier identification appears to be adequate, as the observed frequency of carriers among the A G U rel:ttives was in agreement with the theoretical expectations. This is the optimal method of evaluating a hetero/ygote detection method. as mentioned by Kaback and coworkers ( I I).
The incidence of A G U in Finland has been estimated roughly to be in the order of 1 in 26,000 (3), suggesting the overall carrier frequency of A G U t o be about 1 in 80. W e consider this too low t o justify large scale screening programs for heterozygote detection, at least with the presently available methods. However, carrier detection among the relatives of known A G U patients is medically, economically, and psychologically advantageous, particu-AULA, RAIVIO, AND AUTlO Siblings of Offspring of A G U p a t i e n t s h e t e r o z y g o t e s larly since prenatal diagnosis and the possibility of preventive abortion can be offered to carrier-carrier matings.
The use of separated lymphocytes for heterozygote detection has previously been reported only in Gaucher's disease (4). Distinction of heterozygotes from normal individuals by P-glucosidase activity was clearly better with Ficoll-separated lymphocytes than with mixed leukocytes or granulocytes. Even with lymphocytes there was some overlap between the enzyme activities in the two groups.
In a majority of inherited enzyme defects, particularly those of lysosomal hydrolases, heterozygous levels of the enzyme activity are demonstrable in an easier fashion using either serum (plasma) as in Tay-Sachs' disease and Krabbe's disease or buffy coat leukocytes as in metachromatic leukodystrophy, Fabry's disease, Niemann-Pick's disease, Wolman's disease, and in some other genetic enzyme defects (see Reference 6) .
In acid phdsphatase deficiency, separated lymphocytes (glass bead column separation) could not be reliably used t o distinguish heterozygotes from normal individuals, but after 56 hr of culture with phytohemagglutinin stimulation a distinct differentiation was possible (16) . Also in glycogenosis type I 1 unstimulated lymphocytes were not suitable for the demonstration of the heterozygous level of a-glucosidase activity, but in phytohemagglutininstimulated lymphocytes the heterozygotes could be distinguished
( 7 ) .
The lymphocytes constitute a more homogeneous cell population than leukocytes, which probably accounts for the better distinction of AADGase activity in heterozygotes and normal individuals. It is possible that enzyme assays in separated lymphocytes could offer possibilities for heterozygote detection in some other lysosomal storage diseases in which serum or leukocytes are not suitable for that purpose. For instance, in mannosidosis, heterozygote and normal levels of n-mannosidase activity in serum and leukocytes had considerable overlap, and distinction of heterozygotes and normal individuals could be achieved only by calculating ratios between a-mannosidase and other lysosomal enzymes (15) .
SUMMARY
Assay of activity of 4-L-aspartylglycosylamine aniido hydrolase in peripheral blood lymphocytes was found to be reliable for heterozygote detection of aspartylglucosaminuria. Enzyme levels in buffy coat leukocytes, on the other hand, could not distinguish heterozygotes from normal individuals. A G U patients had minimal or nondetectable activity of AADGase in lymphocyte^, leukocytes. and plasma. A group of siblings of A G U patients and of children of identified carriers were investigated with the lymphocyte assay for AADGase. The observed number of heterozygotes was in good agreement with expectations based on Mendelian probabilities. AADGase assay in separated lymphocytes offers possibilities for heterozygote screening among selected high gene frequency populations.
